Maintaining multiple in-house drug discovery programs and continuously selecting new targets
First written in FY2024. 5 of 6 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-08-14.
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In addition, during the current fiscal year, we launched 1 new program and are advancing hit compound discovery.」
As of the end of fiscal 2025, proprietary development comprised 4 programs: 2 for hit compound discovery, 1 for lead compound discovery, and 1 for lead optimization. Meanwhile, 1 program was discontinued after failing to meet the plan. - FY2025-H1AdvancedAnnual report
「During the current interim accounting period, 2 out-licensed programs were each undergoing Phase II clinical trials. In proprietary development, we continued developing 3 programs, while in partnered development, we continued drug discovery programs with 7 partners.」
The company continued development of 3 proprietary programs, while 2 out-licensed programs were undergoing Phase II clinical trials. - FY2024First statedAnnual report
「While conducting research and development on 3 new programs that follow the current ones, we are continuously selecting the next drug discovery targets.」
The company plans to build a portfolio of multiple programs to address drug discovery research, which has a low probability of success.